Vivo Bio Tech Ltd
Incorporated in 1987, Vivo Bio Tech Ltd is a supplier of SPF lab animals and is a breeder
& distributor of rodent models.
- Market Cap ₹ 67.2 Cr.
- Current Price ₹ 45.1
- High / Low ₹ 56.0 / 21.0
- Stock P/E 17.4
- Book Value ₹ 34.8
- Dividend Yield 0.00 %
- ROCE 11.0 %
- ROE 5.39 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 2.13% over past five years.
- Company has a low return on equity of 8.10% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12.48 | 14.37 | 16.13 | 17.79 | 28.58 | 34.13 | 47.00 | 55.83 | 55.35 | 51.78 | 51.39 | 52.23 | 48.45 | |
7.19 | 12.01 | 14.38 | 14.99 | 24.87 | 26.51 | 36.11 | 46.32 | 42.88 | 33.98 | 35.30 | 30.39 | 25.60 | |
Operating Profit | 5.29 | 2.36 | 1.75 | 2.80 | 3.71 | 7.62 | 10.89 | 9.51 | 12.47 | 17.80 | 16.09 | 21.84 | 22.85 |
OPM % | 42.39% | 16.42% | 10.85% | 15.74% | 12.98% | 22.33% | 23.17% | 17.03% | 22.53% | 34.38% | 31.31% | 41.82% | 47.16% |
0.05 | 0.76 | 0.88 | 0.95 | 0.89 | 0.40 | 0.13 | 0.01 | 0.05 | 0.08 | 0.10 | 0.04 | 0.05 | |
Interest | 3.40 | 0.78 | 0.39 | 0.51 | 0.47 | 1.29 | 2.37 | 2.64 | 3.10 | 3.67 | 4.27 | 7.99 | 8.27 |
Depreciation | 2.08 | 1.57 | 1.56 | 3.05 | 3.35 | 3.90 | 4.64 | 5.06 | 5.17 | 5.59 | 7.45 | 9.27 | 9.13 |
Profit before tax | -0.14 | 0.77 | 0.68 | 0.19 | 0.78 | 2.83 | 4.01 | 1.82 | 4.25 | 8.62 | 4.47 | 4.62 | 5.50 |
Tax % | 600.00% | 49.35% | 55.88% | -142.11% | -16.67% | 11.66% | 21.95% | -23.08% | -4.47% | 34.11% | 50.78% | 42.64% | |
0.71 | 0.39 | 0.29 | 0.46 | 0.91 | 2.50 | 3.12 | 2.25 | 4.44 | 5.68 | 2.20 | 2.65 | 3.85 | |
EPS in Rs | 0.76 | 0.42 | 0.31 | 0.49 | 0.97 | 2.67 | 3.17 | 1.82 | 3.45 | 4.23 | 1.54 | 1.78 | 2.58 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 2% |
3 Years: | -2% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | -3% |
3 Years: | -16% |
TTM: | 3950% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | -2% |
3 Years: | -10% |
1 Year: | 84% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 9% |
3 Years: | 8% |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9.35 | 9.35 | 9.35 | 9.35 | 9.35 | 9.35 | 9.85 | 12.35 | 12.89 | 13.42 | 14.26 | 14.90 |
Reserves | -4.43 | -1.12 | -0.83 | -0.18 | 0.71 | 3.22 | 7.36 | 14.62 | 20.14 | 27.68 | 32.18 | 36.97 |
22.92 | 3.58 | 6.62 | 5.69 | 16.91 | 27.06 | 25.12 | 21.68 | 24.37 | 30.96 | 67.44 | 62.39 | |
26.29 | 26.86 | 24.90 | 26.57 | 18.69 | 11.49 | 17.18 | 6.67 | 6.29 | 7.46 | 8.60 | 8.77 | |
Total Liabilities | 54.13 | 38.67 | 40.04 | 41.43 | 45.66 | 51.12 | 59.51 | 55.32 | 63.69 | 79.52 | 122.48 | 123.03 |
43.14 | 20.73 | 20.59 | 19.69 | 23.54 | 28.57 | 27.66 | 30.01 | 34.99 | 52.05 | 95.17 | 88.87 | |
CWIP | 0.88 | 0.00 | 0.00 | 0.07 | 0.04 | 2.96 | 3.94 | 0.07 | 0.15 | 0.32 | 0.87 | 1.90 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
10.11 | 17.94 | 19.45 | 21.67 | 22.08 | 19.59 | 27.91 | 25.24 | 28.55 | 27.15 | 26.44 | 32.26 | |
Total Assets | 54.13 | 38.67 | 40.04 | 41.43 | 45.66 | 51.12 | 59.51 | 55.32 | 63.69 | 79.52 | 122.48 | 123.03 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4.66 | 2.12 | 2.79 | 2.25 | 8.81 | -5.66 | 11.11 | -0.78 | 8.61 | 14.18 | 16.64 | 14.83 | |
-4.58 | 25.03 | -1.42 | -2.04 | -7.20 | -11.84 | -4.72 | -3.53 | -10.23 | -22.82 | -51.11 | -4.00 | |
0.11 | -19.33 | -0.44 | -0.89 | -0.32 | 6.83 | -3.43 | 0.72 | 2.09 | 8.78 | 35.02 | -11.18 | |
Net Cash Flow | 0.19 | 7.82 | 0.93 | -0.68 | 1.30 | -10.67 | 2.96 | -3.59 | 0.47 | 0.14 | 0.55 | -0.34 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 153.55 | 102.36 | 97.30 | 88.43 | 48.79 | 82.03 | 91.48 | 54.98 | 69.11 | 51.39 | 85.37 | 86.52 |
Inventory Days | 2.35 | 3.92 | 42.06 | 557.61 | 169.23 | 204.47 | 289.48 | 255.75 | 451.13 | 672.29 | 312.99 | 429.70 |
Days Payable | 1,097.35 | 857.55 | 1,160.13 | 814.41 | 362.93 | 242.14 | 304.36 | 152.08 | 166.72 | 70.37 | 74.02 | 50.68 |
Cash Conversion Cycle | -941.45 | -751.27 | -1,020.76 | -168.38 | -144.91 | 44.36 | 76.61 | 158.65 | 353.52 | 653.31 | 324.35 | 465.53 |
Working Capital Days | -521.47 | -456.44 | -343.05 | -291.55 | -95.40 | 84.70 | 73.78 | 119.71 | 131.89 | 143.73 | 131.40 | 172.96 |
ROCE % | 12.39% | 7.82% | 7.94% | 4.67% | 5.98% | 12.37% | 15.57% | 9.80% | 13.86% | 18.99% | 9.40% | 11.05% |
Documents
Announcements
- Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 For The Year Ended March 31, 2024 22 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 20 Apr
- Certificate Under Regulation 7(3) Of The SEBI (LODR) Regulations, 2015 For The Year Ended March 31, 2024 13 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Apr - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
- Closure of Trading Window 28 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Vivo Bio Tech is a full-service CRO offering
drug development & discovery services
to pharmaceutical & biotech companies.
The company provides both regulatory and
non-regulatory IND-enabling preclinical development services, screening and evaluating molecules for various pharmacological & therapeutic properties. Specifically for oncology,
the company provides design & development
of syngeneic/xenograft models for evaluation
of anti-cancer agents. Further, the company can customize In vivo DMPK studies to help profile drug candidates in both rodent and non-rodent animal models.